Breaking News

LGC Acquires Quotient’s Bioanalytical Business

January 2, 2013

Expands range of products and services

LGC has reached an agreement to acquire Quotient Bioresearch’s Bioanalytical Sciences division. That business unit, based at Fordham, Cambridgeshire, UK, provides bioanalytical services across the fields of small molecules, biomarkers, biopharmaceuticals and microbiological testing to the pharmaceutical and biotechnology sectors.
Quotient and LGC will collaborate as preferred partners on the provision of Bioanalytical Sciences. The Bioanalytical Sciences business will continue to trade using the Quotient name under its new ownership.
Jeremy Cook, managing director of LGC’s Health Sciences, said, “We’re delighted to have acquired Quotient Bioanalytical Sciences, a high-quality business that is complementary to our existing activities. We continue to develop our range of first-rate services in the pharmaceutical, biotechnology and agrochemical sectors by offering our customers a unique mix of technical experience, leading edge facilities and knowledgeable people.”
Dr. Steve Pleasance, managing director of Quotient Bioanalytical Sciences, said, “LGC’s focus on complex analytical chemistry, high quality science and service delivery make them a natural home for our business. Both our organizations have reputations built upon quality and innovation and LGC’s global presence will help support the continued growth of services to our customers.”
blog comments powered by Disqus
  • Elemental Impurity Testing

    Elemental Impurity Testing

    Dr. Andrew Fussell, PANalytical ||January 28, 2016
    Advances in elemental impurity testing aid compliance with new USP requirements

  • Fit-For-Purpose Assay Development in Bioanalysis

    Fit-For-Purpose Assay Development in Bioanalysis

    Franklin Spriggs, Ligand Binding Assay Group Leader; Ashley Brant, Program Manager, AIT Bioscience||January 28, 2016
    The success of bioanalytical studies relies on the selection of the most suitable analytical method but the timeline of method development and types of analyses involved vary greatly.

  • Biopharmaceutical Contract Manufacturing Capacity Expansions

    Biopharmaceutical Contract Manufacturing Capacity Expansions

    William Downey , HighTech Business Decisions||June 2, 2015
    Biopharma contract manufacturing market continues to expand, expected to grow 8% over the next five years